Regeneron Pharmaceuticals, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +5.9%
EBITDA: +3.9%
EBIT: -5.3%
EPS: +1.8%
Free cash flow: +37.6%
Operating cash flow: +26.8%

Forward estimates

Revenue: +14.3%
EBITDA: +28.9%
EPS: +18.6%

Three-year CAGR

Revenue: +5.6%
EBITDA: +3.4%
EBIT: -12.7%
Net income: +1.3%
EPS: +2.1%
Free cash flow: -2.7%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.